article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Accretion Pharmaceuticals’ IPO to open on May 14 2025; Price band fixed at ₹96-101

Express Pharma

Accretion Pharmaceuticals manufactures medicines for the treatment of a variety of conditions, including cardiovascular, anti-diabetic, anti-fungal, anti-allergic, pain management, vitamins and nutrition, anti-bacterials, anti-ulcerants, and neuropathy management. The company has registered 35.66 crore in the fiscal year 2024.

article thumbnail

AZ boasts phase 3 win for self-administered gMG drug

pharmaphorum

Skip to main content Thursday 24 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

The rise of Fixed-Dose Combinations (FDCs): What it means for pharma players

Express Pharma

Factors driving the growth of FDCs One of the primary reasons for the rise of FDCs has been their role in addressing diseases that require multi-drug therapy, such as tuberculosis, cardiovascular conditions, diabetes, and infectious diseases. Rifampicin + Isoniazid + Ethambutol) Antimalarial combinations (e.g.,

article thumbnail

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Hypertension: A Silent Killer Requiring Novel Therapies

Pharmacy Times

2018 ESC/ESH guidelines for the management of arterial hypertension. 2018; 39: 3021–3104. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71:e127-e248. doi:10.1016/j.jacc.2017.11.006 2017.11.006 Williams B, Mancia G, Spiering W, et al. Eur Heart J.